Amicus Therapeutics, Inc. (FOLD) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $14.49 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away).
Amicus Therapeutics developed and sold rare disease therapies: Galafold (migalastat, oral Fabry disease monotherapy approved in 40+ countries) generated $521.7 million in 2025 revenue, and Pombiliti + Opfolda (Pompe disease treatment) generated $112.5 million. On April 27, 2026,... Read more
Sell if holding. Analyst target reached at $14.49 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About Amicus Therapeutics, Inc.
About Amicus Therapeutics, Inc.
Amicus Therapeutics generated $521.7 million in Galafold revenue and $112.5 million in Pombiliti + Opfolda revenue for the year ended December 31, 2025. Galafold, the first oral monotherapy for Fabry disease patients with amenable GLA variants, is approved in over 40 countries including the U.S. (FDA August 2018 accelerated approval), EU, UK, and Japan; Pombiliti + Opfolda received approval in the U.S., EU, UK, Canada, Australia, Switzerland, and Japan for adult late-onset Pompe disease. The company held $293.5 million in cash and marketable securities at year-end 2025.
Amicus earns revenue through prescription sales to patients with rare lysosomal storage disorders via its own commercial infrastructure in the U.S., Europe, and Japan, supplemented by third-party distribution in other territories. Galafold targets 35-50% of the Fabry patient population with amenable GLA variants; competing treatments include enzyme replacement therapies from Sanofi Aventis (agalsidase beta), Chiesi Farmaceutici (pegunigalsidase alfa-iwxj), and Takeda (agalsidase alfa, not U.S.-approved). Pombiliti + Opfolda competes with two Sanofi ERTs in the Pompe market. Under the GlaxoSmithKline Collaboration Agreement, GSK is eligible for up to $40 million in post-approval and sales-based milestones, plus tiered royalties in the mid-teens in eight major non-U.S. markets for Galafold. In April 2025, the company paid $30 million to in-license DMX-200 for FSGS from Dimerix Bioscience, a Phase 3 candidate with enrollment in ACTION3 completed in December 2025.
Show full overview
Galafold U.S. Orange Book patents expire between 2027 and 2042, with generic entry deferred until January 30, 2037 via non-exclusive licenses granted to Teva (October 2024), Aurobindo, and Lupin (December 2025), resolving Hatch-Waxman litigation from 2022 Paragraph IV certifications. However, Galafold carries FDA accelerated approval rather than traditional approval, and the 10-K notes that adverse Phase 4 study results could substantially diminish commercial success prior to the 2037 generic entry date. A royalty obligation to GSK covering mid-teens percentage of net sales in eight markets reduces net revenue captured per Galafold unit sold outside the U.S.
See also: Healthcare · Biotechnology
From Amicus Therapeutics, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $14.49 — A.R:R is negative (-0.9) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Near 52-week high (0.1% away). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.45. Score 5.7/10, moderate confidence.
Take-profit target: $14.21 (-1.9% upside). Prior stop was $14.45. Stop-loss: $14.45.
Analyst target reached - limited upside remaining; Near 52-week high (0.1% away); Leverage penalty (D/E 1.6): -1.0.
Amicus Therapeutics, Inc. trades at a P/E of N/A (forward 17.7). TrendMatrix value score: 6.2/10. Verdict: Sell.
14 analysts cover FOLD with a consensus score of 3.6/5. Average price target: $15.
What does Amicus Therapeutics, Inc. do?Amicus Therapeutics developed and sold rare disease therapies: Galafold (migalastat, oral Fabry disease monotherapy...
Amicus Therapeutics developed and sold rare disease therapies: Galafold (migalastat, oral Fabry disease monotherapy approved in 40+ countries) generated $521.7 million in 2025 revenue, and Pombiliti + Opfolda (Pompe disease treatment) generated $112.5 million. On April 27, 2026, BioMarin Pharmaceutical completed its acquisition of Amicus at $14.50 per share in cash.